Physician profile

Audrey Sim

General Practice (Dentist) · Algonquin, IL

NPI 1992900021

$252.46

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$114.56

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Orapharma, A Division of Bausch Health US, LLC $58.50 2021-2022
Align Technology, INC. $49.82 2021-2023 Itero Element Flex
Dentsply Sirona INC $44.82 2023 Tph Spectra Universal Composite Restorative Low Viscosity
Philips North America LLC $39.23 2022-2024 (L00) Whitening
Gc America INC. $29.21 2021-2022
Zimvie INC. $19.05 2023
Voco America INC. $11.83 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Audrey Sim

$252.46

in general payments reported 2019-2025

Years
2021-2024
Top company
Orapharma, A Division of Bausch Health US, LLC

https://glasscript.com/doctor/181477/audrey-sim

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.